Detecting Low-Abundance Biomarkers in Blood and CSF: Challenges and Solutions
High-sensitivity biomarker platforms are revolutionizing clinical neuroscience, but significant challenges remain. The blood-brain barrier, complex matrices, and the ultra-low abundance of biomarkers such as mutant huntingtin and amyloid-beta often limit the precision of early disease detection and therapeutic monitoring.
In this vodcast, two biomarker experts delve into practical solutions using ultra-sensitive technologies and validated workflows that are advancing precision medicine in neuroscience.
What You’ll Learn:
- Why low-abundance biomarkers are critical for patient stratification in CNS trials
- How platforms like Simoa®, SMCxPro®, and NULISA™ enable detection in blood and CSF
- Practical approaches for validating biomarker assays across global clinical sites
- The role of biomarkers in improving trial reproducibility and regulatory readiness
Ideal for translational scientists, biomarker leads, and clinical development teams, this Expert Talk offers actionable insights to improve biomarker strategies in neurodegenerative disease trials.
Meet the Experts:
Elizabeth van der Kam, SVP Global Translational Biomarkers
Barbara Baldo, Group Leader, Translational Biomarkers
Offered Free by: Evotec International GmbH
See All Resources from: Evotec International GmbH
